Comparison of Rheumatoid Arthritis Composite Disease Activity Indices and Residual Activity in a Brazilian Multicenter Study- REAL Study

Introduction: Rheumatoid arthritis (RA) composite disease activity indices have become handy tools in daily clinical practice and crucial in defining remission or low disease activity, the main target of the RA treatment. However, there is no definition of the best index to assess disease activity in clinical practice.

Objectives: To compare the residual activity among the indices with the ACR/EULAR remission criteria (Boolean method) to identify the most feasible for assessing remission in daily practice, also considering correlation and concordance, sensibility, and specificity.

Patients And Methods: We selected 1116 patients with established RA from the real-life rheumatoid arthritis study database-REAL. The composite disease activity indices-DAS28-ESR, DAS28-CRP, SDAI, and CDAI-and their components were compared to the Boolean method to identify residual activity using binomial regression. The indices were analyzed for correlation and agreement using the Spearman index and weighted kappa. The chi-square test evaluated sensibility and specificity for remission based on the Boolean method.

Results: DAS28-CRP overestimated remission and confirmed higher residual activity than SDAI and CDAI. The indices showed good correlation and agreement, with a better relationship between SDAI and CDAI (k:0,88). CDAI and SDAI showed higher sensitivity and specificity for remission based on the Boolean method. CDAI was performed in 99% of patients, while DAS28 and SDAI were completed in approximately 85%.

Conclusions: Although all composite indices of activity can be used in clinical practice and showed good agreement, CDAI and SDAI have better performance in evaluating remission based on the Boolean method, showing less residual activity and higher sensibility and specificity. In addition, CDAI seems to be more feasible for disease activity evaluation in daily clinical practice, especially in developing countries.

References

Gomides A, de Albuquerque C, Vargas Santos A, Balbino Chaves Amorim R, Bertolo M, Junior P . Causes of synthetic disease-modifying drug discontinuation in rheumatoid arthritis: Data from a large real-life cohort. PLoS One. 2019; 14(3):e0213219. PMC: 6396919. DOI: 10.1371/journal.pone.0213219. View

Aletaha D, Smolen J . Remission in rheumatoid arthritis: missing objectives by using inadequate DAS28 targets. Nat Rev Rheumatol. 2019; 15(11):633-634. DOI: 10.1038/s41584-019-0279-6. View

Mathew A, Danda D, Conaghan P . MRI and ultrasound in rheumatoid arthritis. Curr Opin Rheumatol. 2016; 28(3):323-9. DOI: 10.1097/BOR.0000000000000282. View

Olmez M, Gunal E, Bakirci Ureyen S, Keskin H, Ozturk A, Yeter G . Comparison of composite indices with global synovitis score on ultrasound for detecting remission. Clin Rheumatol. 2017; 37(4):1111-1114. DOI: 10.1007/s10067-017-3925-x. View

Cross M, Smith E, Hoy D, Carmona L, Wolfe F, Vos T . The global burden of rheumatoid arthritis: estimates from the global burden of disease 2010 study. Ann Rheum Dis. 2014; 73(7):1316-22. DOI: 10.1136/annrheumdis-2013-204627. View

Baker J, Conaghan P, Smolen J, Aletaha D, Shults J, Emery P . Development and validation of modified disease activity scores in rheumatoid arthritis: superior correlation with magnetic resonance imaging-detected synovitis and radiographic progression. Arthritis Rheumatol. 2014; 66(4):794-802. DOI: 10.1002/art.38304. View

Smolen J, Aletaha D, Barton A, Burmester G, Emery P, Firestein G . Rheumatoid arthritis. Nat Rev Dis Primers. 2018; 4:18001. DOI: 10.1038/nrdp.2018.1. View

Arnett F, Edworthy S, Bloch D, McShane D, Fries J, Cooper N . The American Rheumatism Association 1987 revised criteria for the classification of rheumatoid arthritis. Arthritis Rheum. 1988; 31(3):315-24. DOI: 10.1002/art.1780310302. View

Hodkinson B, Musenge E, Tikly M . Tight control of rheumatoid arthritis in a resource-constrained setting: a randomized controlled study comparing the clinical disease activity index and simplified disease activity index. Rheumatology (Oxford). 2014; 54(6):1033-8. DOI: 10.1093/rheumatology/keu443. View

10.

Brandao Resende Guimaraes M, da Costa Pinto M, Resende G, Machado C, Vargas-Santos A, Balbino Chaves Amorim R . Discordance between the patient's and physician's global assessment in rheumatoid arthritis: Data from the REAL study-Brazil. PLoS One. 2020; 15(3):e0230317. PMC: 7069615. DOI: 10.1371/journal.pone.0230317. View

11.

Barczynska T, Dura M, Blumfield E, Wegierska M, Zuchowski P, Wilinska-Jankowska A . DAS28 score vs. ultrasound examination for assessment of rheumatoid arthritis disease activity: comparison and discussion of pros and cons. Reumatologia. 2016; 53(4):213-8. PMC: 4847288. DOI: 10.5114/reum.2015.53999. View

12.

Gomides A, de Albuquerque C, Vargas Santos A, Bertolo M, Junior P, Giorgi R . Rheumatoid artrhitis treatment in Brazil: data from a large real-life multicenter study. Adv Rheumatol. 2020; 60(1):16. DOI: 10.1186/s42358-020-0119-z. View

13.

Schoels M, Alasti F, Smolen J, Aletaha D . Evaluation of newly proposed remission cut-points for disease activity score in 28 joints (DAS28) in rheumatoid arthritis patients upon IL-6 pathway inhibition. Arthritis Res Ther. 2017; 19(1):155. PMC: 5496440. DOI: 10.1186/s13075-017-1346-5. View

14.

Padovano I, Costantino F, Breban M, DAgostino M . Prevalence of ultrasound synovial inflammatory findings in healthy subjects. Ann Rheum Dis. 2015; 75(10):1819-23. DOI: 10.1136/annrheumdis-2015-208103. View

15.

Dhaon P, Das S, Srivastava R, Dhakad U . Performances of Clinical Disease Activity Index (CDAI) and Simplified Disease Activity Index (SDAI) appear to be better than the gold standard Disease Assessment Score (DAS-28-CRP) to assess rheumatoid arthritis patients. Int J Rheum Dis. 2017; 21(11):1933-1939. DOI: 10.1111/1756-185X.13110. View

16.

Aletaha D, Nell V, Stamm T, Uffmann M, Pflugbeil S, Machold K . Acute phase reactants add little to composite disease activity indices for rheumatoid arthritis: validation of a clinical activity score. Arthritis Res Ther. 2005; 7(4):R796-806. PMC: 1175030. DOI: 10.1186/ar1740. View

17.

Aletaha D, Smolen J . Achieving Clinical Remission for Patients With Rheumatoid Arthritis. JAMA. 2019; 321(5):457-458. DOI: 10.1001/jama.2018.21249. View

18.

Gomides A, Albuquerque C, Santos A, Amorim R, Bertolo M, Junior P . High Levels of Polypharmacy in Rheumatoid Arthritis-A Challenge Not Covered by Current Management Recommendations: Data From a Large Real-Life Study. J Pharm Pract. 2019; 34(3):365-371. DOI: 10.1177/0897190019869158. View

19.

Shin K, Kim S, Lee S, Hong S, Choi S, Choe J . Simplified disease activity changes in real-world practice: a nationwide observational study of seropositive rheumatoid arthritis patients with moderate-to-high disease activity. Korean J Intern Med. 2019; 35(1):231-239. PMC: 6960052. DOI: 10.3904/kjim.2018.137. View

20.

Smolen J, Aletaha D, McInnes I . Rheumatoid arthritis. Lancet. 2016; 388(10055):2023-2038. DOI: 10.1016/S0140-6736(16)30173-8. View